AGEs and chronic subclinical inflammation in diabetes: disorders of immune system

Hu, Hang; Jiang, Hongfei; Ren, Haitao; Hu, Xiaofan; Wang, Xingang; Han, Chunmao

doi:10.1002/dmrr.2560

Cited by 82 publications

(47 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6,7 RAGE activation is also involved in BBB damage in a variety of human brain disorders, including multiple sclerosis, diabetes mellitus, and Alzheimer disease. [8][9][10] Indeed, inflammatory responses, increased BBB permeability, and brain edema are significantly reduced after brain trauma in RAGE knockout rats. 11 Furthermore, intravenous injection of anti-HMGB1 monoclonal antibodies attenuates ischemic BBB damage.…”

mentioning

confidence: 98%

Receptor for Advanced Glycation End-Product Antagonist Reduces Blood–Brain Barrier Damage After Intracerebral Hemorrhage

Yang

Wang

Zhang³

et al. 2015

Stroke

View full text Add to dashboard Cite

Background and Purpose-To determine whether the receptor for advanced glycation end-products (RAGE) plays a role in early brain injury from intracerebral hemorrhage (ICH), RAGE expression and activation after injury were examined in a rat model of ICH with or without administration of a RAGE-specific antagonist (FPS-ZM1). Methods-Autologous arterial blood was injected into the basal ganglia of rats to induce ICH. The motor function of the rats was examined, and water content was detected after euthanization. Blood-brain barrier permeability was determined by Evans blue staining and colloidal gold nanoparticle tracers. Nerve fiber injury in white matter was determined by diffusion tensor imaging analysis, and the expression of target genes was analyzed by Western blotting and quantitative reverse transcription polymerase chain reaction. FPS-ZM1 was administered by intraperitoneal injection. Results-Expression of RAGE and its ligand high-mobility group protein B1 were increased at 12 hours after ICH, along with blood-brain barrier permeability and perihematomal nerve fiber injury. RAGE and nuclear factor-κB p65 upregulation were also observed when FeCl 2 was infused into the basal ganglia at 24 hours. FPS-ZM1 administration resulted in significant improvements of blood-brain barrier damage, brain edema, motor dysfunction, and nerve fiber injury, and the expression of RAGE, nuclear factor-κB p65, proinflammatory mediators interleukin 1β, interleukin-6, interleukin-8R, cyclooxygenase-2, inducible nitric oxide synthase, and matrix metallopeptidase-9 was attenuated. Moreover, decreases in claudin-5 and occludin expression were partially recovered. FPS-ZM1 also reversed FeCl 2 -induced RAGE and nuclear factor-κB p65 upregulation. Conclusions-RAGE signaling is involved in blood-brain barrier and white matter fiber damage after ICH, the initiation of which is associated with iron. RAGE antagonists represent a novel therapeutic intervention to prevent early brain injury after ICH. .).The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl

show abstract

mentioning

confidence: 98%

Receptor for Advanced Glycation End-Product Antagonist Reduces Blood–Brain Barrier Damage After Intracerebral Hemorrhage

Yang

Wang

Zhang³

et al. 2015

Stroke

View full text Add to dashboard Cite

show abstract

“…, Hu et al. ). Activation of RAGE influences the development of systemic diabetic complications such as diabetic renal disease, as previously reviewed (Yan et al.…”

mentioning

confidence: 99%

Effects of TNF‐α blocking on experimental periodontitis and type 2 diabetes in obese diabetic Zucker rats

Grauballe

Østergaard

Schou

et al. 2015

J Clinic Periodontology

View full text Add to dashboard Cite

show abstract

“…, Hu et al . ). Recently, it has been reported that, under diabetic pulp conditions, AGEs increase mRNA expression of IL‐1β in dental pulp cells through the RAGE‐MAPK signalling pathway (Nakajima et al .…”

Section: Association Between Endodontics and Diabetes Mellitusmentioning

confidence: 97%

Endodontic medicine: connections between apical periodontitis and systemic diseases

2015

View full text Add to dashboard Cite

The prevalence of apical periodontitis (AP) in Europe has been reported to affect 61% of individuals and 14% of teeth, and increase with age. Likewise, the prevalence of root canal treatment (RCT) in Europe is estimated to be around 30-50% of individuals and 2-9% of teeth with radiographic evidence of chronic persistent AP in 30-65% of root filled teeth (RFT). AP is not only a local phenomenon and for some time the medical and dental scientific community have analysed the possible connection between apical periodontits and systemic health. Endodontic medicine has developed, with increasing numbers of reports describing the association between periapical inflammation and systemic diseases. The results of studies carried out both in animal models and humans are not conclusive, but suggest an association between endodontic variables, that is AP and RCT, and diabetes mellitus (DM), tobacco smoking, coronary heart disease and other systemic diseases. Several studies have reported a higher prevalence of periapical lesions, delayed periapical repair, greater size of osteolityc lesions, greater likelihood of asymptomatic infections and poorer prognosis for RFT in diabetic patients. On the other hand, recent studies have found that a poorer periapical status correlates with higher HbA1c levels and poor glycaemic control in type 2 diabetic patients. However, there is no scientific evidence supporting a causal effect of periapical inflammation on diabetes metabolic control. The possible association between smoking habits and endodontic infection has also been investigated, with controversial results. The aim of this paper was to review the literature on the association between endodontic variables and systemic health (especially DM and smoking habits).

show abstract

AGEs and chronic subclinical inflammation in diabetes: disorders of immune system

Cited by 82 publications

References 114 publications

Receptor for Advanced Glycation End-Product Antagonist Reduces Blood–Brain Barrier Damage After Intracerebral Hemorrhage

Receptor for Advanced Glycation End-Product Antagonist Reduces Blood–Brain Barrier Damage After Intracerebral Hemorrhage

Effects of TNF‐α blocking on experimental periodontitis and type 2 diabetes in obese diabetic Zucker rats

Endodontic medicine: connections between apical periodontitis and systemic diseases

Contact Info

Product

Resources

About